Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00197795
: September 20, 2005
Last Update Posted
: March 28, 2012
Public Health England
Information provided by (Responsible Party):
Dr. Elizabeth Miller, Health Protection Agency, United Kingdom
To measure the serum bactericidal antibody levels and cell mediated immune responses before and six weeks after each dose of meningococcal outer membrane vesicle vaccine given at 0,6 and 12 weeks to healthy UK adults.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Informed written consent given for three immunizations with MenBVac and five blood tests
Between the ages of 18 and 55 years inclusive at recruitment
Previous history of bacteriologically confirmed meningococcal disease
History of clinically significant allergic sensitivity to any vaccine received in the past
Any other acute or chronic systemic illness or dependence or abuse of drugs or alcohol
Language difficulties sufficient to preclude adequate comprehension of the study information
Possibility of pregnancy
Receipt of any other vaccine in the previous 4 weeks
Receipt of any group B vaccine in the past
Current participation in any other clinical trial
Generalized acute systemic illness and/or temp >38C on day of vaccination deferral